Novartis to buy kidney-focused biotech built around Nobel-winning discovery for $800M

Taking stock of the drug industry, from the lab to the medicine chest

April 30, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Anna Yeo/STAT STAT+ | Novartis to buy kidney-focused biotech built around Nobel-winning discovery for $800 million The deal, which includes another $900 million in milestone payments, could help Novartis expand its burgeoning kidney disease line. By Jason Mast STAT+ | NIH plans to reduce animal testing in federally funded research "With this initiative, NIH is ushering in a new era of innovation," said the agency's director, Jay Bhattacharya. By Ed Silverman Will the FDA approve the first new drug to help people quit smoking in 20 years? Firm working on first new stop smoking drug in nearly 20 years will seek FDA approval in June for cytisinicline, promises fewer side effects than Chantix. By Sarah Todd

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser